Dos Santos, Gaël http://orcid.org/0000-0001-8623-3478
Devadiga, Raghavendra http://orcid.org/0000-0002-3224-6043
Kim, Chun Soo http://orcid.org/0000-0003-3888-334X
Bang, Joon http://orcid.org/0000-0002-2728-9727
Funding for this research was provided by:
GlaxoSmithKline Biologicals SA
Article History
Accepted: 9 January 2024
First Online: 14 March 2024
Declarations
:
: GlaxoSmithKline Biologicals SA funded this study (GSK Study ID 204687) and was involved in all stages of the study. GlaxoSmithKline Biologicals SA also funded all costs associated with the development and the publishing of the present manuscript.
: Gaël Dos Santos was employed by GSK at the time of the study and holds shares in GSK. Raghavendra Devadiga and Joon Bang are employed by GSK. Chun Soo Kim discloses providing support for the present manuscript for provision of study materials and for medical writing of the study report. Joon Bang was employed by Sanofi Pasteur, Korea, until 5 January 2021. All authors declare no other financial or non-financial relationships and activities and no conflict of interest.
: Anonymised individual participant data and study documents can be requested for further research from ExternalRef removed.
: The study was conducted according to the local rules and regulations of the Korean MFDS. The study was reviewed and approved by the independent review board (IRB) at participating institutions where an IRB was available. Ethics approval numbers for these sites are presented in Supplementary Table 1.
: All subjects or their parent/legally accepted representative provided signed informed consent for the collection and handling of the personal and safety information before enrolment.
: Not applicable.
: Not applicable.
: Fluarix Tetra is a trademark owned by or licensed to GSK.
: GDS led and wrote the first draft of the manuscript. All authors participated in the design or implementation or analysis, and interpretation of the study, and the development of this manuscript. All authors had full access to the data and gave final approval before submission. The authors are solely responsible for the final content and received no financial support or other form of compensation related to the development of the manuscript. The material is original and has not been submitted elsewhere.